MCM5检测非肌层浸润性膀胱癌复发的前瞻性多中心盲法研究
该研究在21个欧洲中心纳入1431例非肌层浸润性膀胱癌随访患者,以膀胱镜及病理为金标准评估ADXBLADDER-MCM5检测复发的准确性。总体敏感度44.9%,特异度71.1%,阴性预测值93%;对非pTaLG肿瘤敏感度75.6%,阴性预测值99.0%。结论认为该检测可排除最具侵袭性肿瘤,有望纳入随访策略。
要点
- ADXBLADDER-MCM5总体敏感度44.9%,特异度71.1%,阴性预测值93%。
- 对非pTaLG复发肿瘤敏感度75.6%,阴性预测值99.0%。
- 年龄和性别对检测性能无统计学显著影响。
核心结论
- 在非肌层浸润性膀胱癌随访中,ADXBLADDER能排除最具侵袭性肿瘤的存在,阴性预测值达99%。
- 结果提示ADXBLADDER可被纳入非肌层浸润性膀胱癌的随访策略。
研究设计与样本
- 多中心前瞻性盲法研究,在21个欧洲中心开展。
- 纳入1431例符合条件的、前2年内诊断且正在接受膀胱镜随访的非肌层浸润性膀胱癌患者。
- 收集尿液行ADXBLADDER-MCM5检测,并与膀胱镜加病理评估结果比较计算性能特征。
主要发现
- 1431例 eligible 患者中127例诊断为膀胱癌复发。
- ADXBLADDER-MCM5检测膀胱癌复发的总体敏感度为44.9%(95%CI 36.1-54)。
- 对非pTaLG肿瘤的敏感度为75.6%(95%CI 59.7-87.6)。
- 特异度为71.1%(95%CI 68.5-73.5),总体阴性预测值为93%(95%CI 91.2-94.5)。
- 排除非pTaLG复发肿瘤的阴性预测值为99.0%(95%CI 98.2-99.5),年龄或性别对性能无统计学显著差异。
临床怎么用
- 在非肌层浸润性膀胱癌随访中,可考虑将ADXBLADDER-MCM5检测用于排除非pTaLG复发肿瘤,以减少不必要膀胱镜。
- 检测阴性时对非pTaLG复发的排除价值较高(阴性预测值99.0%),但仍需结合临床评估。
局限性
- 总体敏感度44.9%较低,对非pTaLG肿瘤敏感度75.6%,可能漏诊部分复发。
- 特异度71.1%,存在一定假阳性。
- 研究仅针对前2年内诊断的非肌层浸润性膀胱癌随访人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Detection of MCM5 containing cells in urine has been shown to be indicative of the presence of a bladder tumor on primary diagnosis. In this study we evaluate diagnostic performance of ADXBLADDER in patients undergoing cystoscopic surveillance in nonmuscle invasive bladder cancer followup. MATERIALS AND METHODS: A multicenter prospective blinded study was performed at 21 European centers with patients undergoing cystoscopy for nonmuscle invasive bladder cancer surveillance, diagnosed in the preceding 2 years. Urine was collected from all eligible patients and ADXBLADDER-MCM5 testing was performed. Performance characteristics were calculated by comparing MCM5 results to the outcome of cystoscopy plus pathological assessment. RESULTS: Of 1,431 eligible patients enrolled 127 were diagnosed with a bladder cancer recurrence. The overall sensitivity for the ADXBLADDER-MCM5 test in detecting bladder cancer recurrence was 44.9% (95% CI 36.1-54) with a 75.6% sensitivity for nonpTaLG tumors (95% CI 59.7-87.6). Specificity was 71.1% (95% CI 68.5-73.5). The overall negative predictive value was 93% (95% CI 91.2-94.5). However, ADXBLADDER was able to rule out the presence of a nonpTaLG recurrent tumor with a negative predictive value of 99.0% (95% CI 98.2-99.5). No statistically significant differences in the performance of ADXBLADDER were observed as a result of age or sex. CONCLUSIONS: This large blinded prospective study demonstrates that in the followup of patients with nonmuscle invasive bladder cancer ADXBLADDER is able to exclude the presence of the most aggressive tumors with a negative predictive value of 99%. These results indicate that ADXBLADDER could be incorporated in the followup strategy of nonmuscle invasive bladder cancer.
引用
- Roupret M, Gontero P, McCracken SRC, et al. Diagnostic Accuracy of MCM5 for the Detection of Recurrence in Nonmuscle Invasive Bladder Cancer Followup: A Blinded, Prospective Cohort, Multicenter European Study. J Urol. 2020. PMID: 32314931. doi:10.1097/JU.0000000000001084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。